4D Molecular Therapeutics enters $250M ATM equity distribution agreement with Leerink Partners

4D Molecular Therapeutics, Inc.

Company enters Sales Agreement to sell up to $250M common stock via at-the-market offering through Leerink Partners.
Agent compensation up to 3.0% of gross proceeds; sales made on Nasdaq via Rule 415(a)(4).
Offering registered under existing S-3 filed Feb 2024; prospectus supplement filed June 7, 2024.
No minimum sales obligation; company may terminate at any time upon prior notice.
Proceeds for general corporate purposes; no escrow arrangement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.